Literature DB >> 21493738

Infection, inflammation, and lung function decline in infants with cystic fibrosis.

Naveen Pillarisetti1, Elizabeth Williamson, Barry Linnane, Billy Skoric, Colin F Robertson, Phil Robinson, John Massie, Graham L Hall, Peter Sly, Stephen Stick, Sarath Ranganathan.   

Abstract

RATIONALE: Better understanding of evolution of lung function in infants with cystic fibrosis (CF) and its association with pulmonary inflammation and infection is crucial in informing both early intervention studies aimed at limiting lung damage and the role of lung function as outcomes in such studies.
OBJECTIVES: To describe longitudinal change in lung function in infants with CF and its association with pulmonary infection and inflammation.
METHODS: Infants diagnosed after newborn screening or clinical presentation were recruited prospectively. FVC, forced expiratory volume in 0.5 seconds (FEV(0.5)), and forced expiratory flows at 75% of exhaled vital capacity (FEF(75)) were measured using the raised-volume technique, and z-scores were calculated from published reference equations. Pulmonary infection and inflammation were measured in bronchoalveolar lavage within 48 hours of lung function testing.
MEASUREMENTS AND MAIN RESULTS: Thirty-seven infants had at least two successful repeat lung function measurements. Mean (SD) z-scores for FVC were -0.8 (1.0), -0.9 (1.1), and -1.7 (1.2) when measured at the first visit, 1-year visit, or 2-year visit, respectively. Mean (SD) z-scores for FEV(0.5) were -1.4 (1.2), -2.4 (1.1), and -4.3 (1.6), respectively. In those infants in whom free neutrophil elastase was detected, FVC z-scores were 0.81 lower (P=0.003), and FEV(0.5) z-scores 0.96 lower (P=0.001), respectively. Significantly greater decline in FEV(0.5) z-scores occurred in those infected with Staphylococcus aureus (P=0.018) or Pseudomonas aeruginosa (P=0.021).
CONCLUSIONS: In infants with CF, pulmonary inflammation is associated with lower lung function, whereas pulmonary infection is associated with a greater rate of decline in lung function. Strategies targeting pulmonary inflammation and infection are required to prevent early decline in lung function in infants with CF.

Entities:  

Mesh:

Year:  2011        PMID: 21493738     DOI: 10.1164/rccm.201011-1892OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  81 in total

1.  Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from Cystic fibrosis patients.

Authors:  Benjamin T Kopp; Basant A Abdulrahman; Arwa A Khweek; Surender B Kumar; Anwari Akhter; Richard Montione; Mia F Tazi; Kyle Caution; Karen McCoy; Amal O Amer
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

2.  Vaccine strategies against cystic fibrosis pathogens.

Authors:  Vincent Le Moigne; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

Authors:  Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

4.  Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis.

Authors:  Jessica E Pittman; Kristine M Wylie; Kathryn Akers; Gregory A Storch; Joseph Hatch; Jane Quante; Katherine B Frayman; Nadeene Clarke; Miriam Davis; Stephen M Stick; Graham L Hall; Gregory Montgomery; Sarath Ranganathan; Stephanie D Davis; Thomas W Ferkol
Journal:  Ann Am Thorac Soc       Date:  2017-10

5.  AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.

Authors:  Bonnie W Ramsey; Michael J Welsh
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

6.  Changes in Pulmonary Function and Controlled Ventilation-High Resolution CT of Chest After Antibiotic Therapy in Infants and Young Children with Cystic Fibrosis.

Authors:  Shahid I Sheikh; Frederick R Long; Robert Flucke; Nancy A Ryan-Wenger; Don Hayes; Karen S McCoy
Journal:  Lung       Date:  2015-03-12       Impact factor: 2.584

7.  Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis.

Authors:  Camilla Margaroli; Luke W Garratt; Hamed Horati; A Susanne Dittrich; Timothy Rosenow; Samuel T Montgomery; Dario L Frey; Milton R Brown; Carsten Schultz; Lokesh Guglani; Anthony Kicic; Limin Peng; Bob J Scholte; Marcus A Mall; Hettie M Janssens; Stephen M Stick; Rabindra Tirouvanziam
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

8.  Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection.

Authors:  Benjamin J Staudinger; Jocelyn Fraga Muller; Skarphéðinn Halldórsson; Blaise Boles; Angus Angermeyer; Dao Nguyen; Henry Rosen; Olafur Baldursson; Magnús Gottfreðsson; Guðmundur Hrafn Guðmundsson; Pradeep K Singh
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 9.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

Review 10.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.